Leerink Partnrs Forecasts Lower Earnings for Xeris Biopharma

Key Points

• Analysts at Leerink Partners have revised Xeris Biopharma's Q3 2025 earnings per share (EPS) estimate down to $0.01, reflecting a decrease from the previous estimate of $0.02.
• The company reported a Q2 EPS of ($0.01), surpassing analysts' consensus estimates of ($0.03), with revenue of $67.71 million compared to expectations of $64.58 million.
• Xeris Biopharma has received a consensus rating of "Moderate Buy" with a price target of $6.58 from analysts, indicating positive sentiment despite recent EPS adjustments.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) - Research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for Xeris Biopharma in a note issued to investors on Tuesday, August 19th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn $0.01 per share for the quarter, down from their previous estimate of $0.02. The consensus estimate for Xeris Biopharma's current full-year earnings is ($0.41) per share.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The firm had revenue of $67.71 million during the quarter, compared to the consensus estimate of $64.58 million.

Several other research firms have also recently weighed in on XERS. Oppenheimer boosted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Leerink Partners raised their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a research report on Tuesday. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Finally, HC Wainwright started coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They set a "buy" rating and a $10.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Xeris Biopharma presently has an average rating of "Moderate Buy" and a consensus target price of $7.08.

Xeris Biopharma Stock Performance

NASDAQ:XERS traded up $0.16 during mid-day trading on Thursday, hitting $7.75. The company had a trading volume of 1,699,218 shares, compared to its average volume of 3,331,996. The business's fifty day moving average is $5.53 and its two-hundred day moving average is $4.85. Xeris Biopharma has a fifty-two week low of $2.48 and a fifty-two week high of $7.79. The firm has a market cap of $1.25 billion, a P/E ratio of -36.90 and a beta of 0.65.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently modified their holdings of XERS. NewEdge Advisors LLC bought a new stake in shares of Xeris Biopharma in the 4th quarter worth approximately $34,000. Raymond James Financial Inc. acquired a new position in Xeris Biopharma in the fourth quarter valued at approximately $45,000. Two Sigma Advisers LP acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth $47,000. Aquatic Capital Management LLC bought a new stake in Xeris Biopharma in the fourth quarter valued at approximately $50,000. Finally, Apella Capital LLC bought a new stake in Xeris Biopharma in the 1st quarter valued at $55,000. Institutional investors and hedge funds own 42.75% of the company's stock.

Insider Buying and Selling at Xeris Biopharma

In other Xeris Biopharma news, Director Dawn Halkuff sold 42,500 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $7.28, for a total transaction of $309,400.00. Following the transaction, the director directly owned 115,000 shares in the company, valued at approximately $837,200. This represents a 26.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kevin Mcculloch purchased 25,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the completion of the acquisition, the insider owned 1,708,585 shares in the company, valued at $7,483,602.30. This represents a 1.48% increase in their position. The disclosure for this purchase can be found here. 6.47% of the stock is currently owned by corporate insiders.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.